press releases rule

Archives: Search / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

Nov 24, 2014
-- Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria --
Nov 14, 2014
-- Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS --
Nov 6, 2014
-- Conference Call Scheduled for Friday, November 14, 2014, at 8:30 a.m. EST --
Oct 22, 2014
-- First Allowed Patent Application Directly Related to SYN-004 in the U.S. --
Oct 15, 2014
-- Mark Pimentel, M.D., FRCP©, of Cedars-Sinai Medical Center Serves as Chairman --
 

Print Email RSS